Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 PALMIN CERTIFICATION PURSUANT TO SEC 906 - Acer Therapeutics Inc. | acer-ex322_11.htm |
| EX-32.1 - EX-32.1 SCHELLING CERTIFICATION PURSUANT TO SEC 906 - Acer Therapeutics Inc. | acer-ex321_9.htm |
| EX-31.2 - EX-31.2 PALMIN CERTIFICATION PURSUANT TO SEC 302 - Acer Therapeutics Inc. | acer-ex312_7.htm |
| EX-31.1 - EX-31.1 SCHELLING CERTIFICATION PURSUANT TO SEC 302 - Acer Therapeutics Inc. | acer-ex311_12.htm |
| EX-10.22 - EX-10.22 - Acer Therapeutics Inc. | acer-ex1022_390.htm |
| EX-10.7 - EX-10.7 - Acer Therapeutics Inc. | acer-ex107_425.htm |
| 10-K - 10-K - Acer Therapeutics Inc. | acer-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Acer Therapeutics, Inc.
Newton, Massachusetts
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-228319), S-1 (No. 333-238192) and Form S-8 (Nos. 333-237265, 333-230133, 333-224942, 333-221566) of Acer Therapeutics, Inc. of our report dated March 1, 2021, relating to the financial statements which appear in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Boston, Massachusetts
March 1, 2021